Open AccessCurrent state of umbilical cord stem cells in humans
Author(s) -
Sylwia Borys-Wójcik,
Lisa Moncrieff,
Bartosz Kempisty,
Marta Dyszkiewicz-Konwińska
Publication year - 2019
Publication title -
medical journal of cell biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.294
H-Index - 8
ISSN - 2544-3577
DOI - 10.2478/acb-2019-0011
Subject(s) - umbilical cord , wharton's jelly , stem cell , cord lining , mesenchymal stem cell , medicine , adult stem cell , haematopoiesis , transplantation , immunology , microbiology and biotechnology , biology , cancer research , endothelial stem cell , pathology , in vitro , biochemistry
The umbilical cord is an unlimited source of mesenchymal stem cells (MSC) and hematopoietic stem cells (HSC). MSC obtained from the umbilical cord can be differentiated into different types of mesodermal cells, e.g. chondrocytes, osteocytes, adipocytes, and myocytes. It is also worth mentioning that there are reports of MSC differentiation into endo and ectodermal cells. The immunosuppressive properties of MSCs can protect against graft versus host disease as well as prevent rejection after transplantation. Umbilical cord stem cells can be frozen and then stored in liquid nitrogen for many years. In this work, we focused on the use of preclinical and clinical umbilical cord stem cells in disease entities such as type I diabetes, chronic renal failure, and multiple sclerosis. Furthermore, the anti-cancer properties of Wharton’s jelly cells are described. Running title : Umbilical cord stem cells in humans